Have Y-mAbs Therapeutics Insiders Been Selling Stock?
Have Y-mAbs Therapeutics Insiders Been Selling Stock?
Some Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) shareholders may be a little concerned to see that the Founder, Thomas Gad, recently sold a substantial US$841k worth of stock at a price of US$12.02 per share. That's a big disposal, and it decreased their holding size by 17%, which is notable but not too bad.
近期，Y-mAbs Therapeutics, Inc. (納斯達克:YMAB) 的創始人Thomas Gad以12.02美元/股的價格出售了價值8,410,000美元的股票，這一規模很大的交易減少了其17%的股份，儘管該舉動引人注目，但並不太糟糕。
Y-mAbs Therapeutics Insider Transactions Over The Last Year
過去一年中Y-mAbs Therapeutics的內部交易情況
Notably, that recent sale by Founder Thomas Gad was not the only time they sold Y-mAbs Therapeutics shares this year. Earlier in the year, they fetched US$6.83 per share in a -US$1.0m sale. That means that an insider was selling shares at slightly below the current price (US$12.05). When an insider sells below the current price, it suggests that they considered that lower price to be fair. That makes us wonder what they think of the (higher) recent valuation. Please do note, however, that sellers may have a variety of reasons for selling, so we don't know for sure what they think of the stock price. It is worth noting that this sale was only 29% of Thomas Gad's holding.
值得注意的是，Thomas Gad近期出售Y-mAbs Therapeutics股票並不是今年唯一的一次。今年早些時候，他們以6.83美元/股的價格進行了價值1,000,000美元的交易。這意味着內部人員以略低於當前價(12.05美元)的價格出售了股份。當內部人員以低於當前價格出售時，這表明他們認爲較低的價格是公道的。這讓我們想知道他們對(更高的)最近估值有何看法。請注意，賣家出售股份可能有各種各樣的原因，因此我們不能確定他們對股票價格的看法。值得注意的是，這次交易僅佔Thomas Gad持有的股份的29%。
In the last year Y-mAbs Therapeutics insiders didn't buy any company stock. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
在過去一年中，Y-mAbs Therapeutics的內部人員沒有購買過公司的任何股票。下面的圖表顯示了過去一年中公司和個人的內部交易情況。如果您想確切地知道是誰以何種價格在何時出售了股票，請單擊下面的圖表！
I will like Y-mAbs Therapeutics better if I see some big insider buys. While we wait, check out this free list of undervalued and small cap stocks with considerable, recent, insider buying.
如果我們看到一些重要的內部人員買入Y-mAbs Therapeutics股票，則可能會更喜歡該公司。與此同時，請查看這份免費的低估值和小盤股票清單，其中還有大量近期的內部買入。
Insider Ownership Of Y-mAbs Therapeutics
Y-mAbs Therapeutics的內部所有權
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. We usually like to see fairly high levels of insider ownership. It appears that Y-mAbs Therapeutics insiders own 3.0% of the company, worth about US$16m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.
檢驗公司領導人和其他股東之間的協作程度的另一種方法是查看他們擁有的股份數量。我們通常希望看到相當高的內部所有權水平。看起來Y-mAbs Therapeutics的內部人員擁有該公司的3.0%的股份，價值約爲16,000,000美元。我們肯定在其他地方看到過更高的內部所有權水平，但這些持股足以表明內部人員與其他股東之間的協作程度。
What Might The Insider Transactions At Y-mAbs Therapeutics Tell Us?
Y-mAbs Therapeutics的內部交易情況可能會告訴我們什麼？
Insiders sold Y-mAbs Therapeutics shares recently, but they didn't buy any. And even if we look at the last year, we didn't see any purchases. While insiders do own shares, they don't own a heap, and they have been selling. We're in no rush to buy! So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. Every company has risks, and we've spotted 3 warning signs for Y-mAbs Therapeutics (of which 1 is a bit concerning!) you should know about.
內部人員最近出售了Y-mAbs Therapeutics的股票，但他們沒有進行過購買。即使我們回顧過去的一年，我們也沒有看到他們進行過任何的購買。儘管內部人員擁有股份，但規模不大，並且他們一直在減持。我們不急於購買！因此，儘管了解內部人員的買賣行爲很有幫助，但了解公司面臨的風險也同樣重要。每個公司都存在風險，我們已經發現了Y-mAbs Therapeutics的3個預警信號(其中1個有點令人擔憂！)。
Of course Y-mAbs Therapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
當然，Y-mAbs Therapeutics可能不是最好的股票。因此，您可能想查看這份高質量的公司集合。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
對於本文而言，內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置，但不包括衍生交易或間接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋？關於內容有所顧慮？直接和我們聯繫。或者，發送電子郵件至editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論，只使用公正的方法論，我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議，也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意，我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有反饋？關於內容有所顧慮？直接和我們聯繫。或者發送電子郵件至editorial-team@simplywallst.com。
譯文內容由第三人軟體翻譯。